Multiple Assemblies exist for SMTL entry 6p5m
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Anti-Tumor Agent; X-RAY DIFFRACTION 2.65 Å

	SMTL ID 6p5m.1 Ligands 6-(5-methyl-1H-pyrazol-4-yl)-2-[(pyrrolidin-1-yl)methyl]thieno[3,2-d]pyrimidin-4(3H)-one Polypeptides Rho-associated protein kinase 2 Oligo-state monomer
	SMTL ID 6p5m.2 Ligands 6-(5-methyl-1H-pyrazol-4-yl)-2-[(pyrrolidin-1-yl)methyl]thieno[3,2-d]pyrimidin-4(3H)-one Polypeptides Rho-associated protein kinase 2 Oligo-state monomer
	SMTL ID 6p5m.3 Ligands - Polypeptides Rho-associated protein kinase 2 Oligo-state monomer
	SMTL ID 6p5m.4 Ligands - Polypeptides Rho-associated protein kinase 2 Oligo-state monomer
	SMTL ID 6p5m.5 Ligands 6-(5-methyl-1H-pyrazol-4-yl)-2-[(pyrrolidin-1-yl)methyl]thieno[3,2-d]pyrimidin-4(3H)-one Polypeptides Rho-associated protein kinase 2 Oligo-state homo-dimer
	SMTL ID 6p5m.6 Ligands 6-(5-methyl-1H-pyrazol-4-yl)-2-[(pyrrolidin-1-yl)methyl]thieno[3,2-d]pyrimidin-4(3H)-one Polypeptides Rho-associated protein kinase 2 Oligo-state homo-dimer